Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 11964944

    Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases

    The Government of the United States · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11964960

    Pyridinone- and pyridazinone-based compounds and uses thereof

    Tri-Institutional Therapeutics Discovery Institute, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11963533

    Compositions and methods for treating Liberibacter diseases and other bacterial diseases

    The Regents of the University of California · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11965166

    Complement factor B (CFB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11965159

    Compositions and methods for regulating proteins and nucleic acids activities

    The Regents of the University of California · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11965032

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 2024131199

    PH RESPONSIVE CYANINE DYES AND CONJUGATES THEREOF

    BRACCO IMAGING SPA [IT] · Granted Thu Apr 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11970523

    Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11970553

    Heterotandem bicyclic peptide complex

    BicycleTx Limited · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11970483

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11969522

    Use of immune modulators to improve nerve regeneration

    The Board of Regents of the University of Texas System · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11970521

    Neuroprotective beta amyloid core peptides and peptidomimetic derivatives

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11970502

    Macrocyclic antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11970543

    Anti-CD39 antibodies and use thereof

    Arcus Biosciences, Inc. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11969444

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11969475

    Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11970479

    3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

    MSD R&D (China) Co. Ltd. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11970538

    Multispecific binding constructs against checkpoint molecules and uses thereof

    Compass Therapeutics LLC · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11969401

    Compositions and methods for treating or limiting development of age-related macular degeneration

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11969408

    Method for improving mitophagy in subjects

    Amazentis SA · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11969435

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11970555

    Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)

    BicycleTx Limited · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11970554

    Labeled oxytocin and method of manufacture and use

    TONIX PHARMACEUTICALS HOLDING CORP · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11970711

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11971410

    Methods of classifying response to immunotherapy for cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11970482

    Acetal compounds and therapeutic uses thereof

    Ligand Pharmaceuticals Incorporated · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11970534

    Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11970457

    Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine

    VTV THERAPEUTICS LLC · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11969511

    Methods and compositions for antimicrobial treatment

    The Board of Regents of the University of Texas System · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11969501

    Auris formulations for treating otic diseases and conditions

    The Regents of the University of California · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11969499

    Hydrogel delivery of sting immunotherapy for treatment cancer

    The Board of Regents of the University of Texas System · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11969470

    Topiramate compositions and methods of making and using the same

    Regents of the University of Minnesota · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11969424

    Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

    TENAX THERAPEUTICS, INC. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11969466

    Stabilized influenza hemagglutinin stem region trimers and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11969404

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. CN 117980330

    Homodimeric peptides and antibodies comprising same

    PAXTRADIA MAB SCIENCE AB · Granted Fri May 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Apr 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11975035

    Methods for treating microbial infections using caudovirales bacteriophages

    The Regents of the University of California · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11975066

    Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof

    SAB Biotherapeutics, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11974992

    Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy

    The Regents of the University of California · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11975045

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11974989

    Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

    VTV THERAPEUTICS LLC · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11975028

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11975056

    AADC polynucleotides for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Provectus Pharmatech, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11975082

    Production of antibacterial and regenerative dental composite using supportive phases (fillers) antibacterial and bioactive properties of which are improved

    AVRUPA IMPLANT SANAYI VE DIS TICARET LIMITED SIRKETI · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11975022

    Trace element compositions, methods of making and use

    American Regent, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11976299

    Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.